Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Form 8.3 - The Vanguard Group, Inc.: AVEVA Group plc
Form 8.3 - The Vanguard Group, Inc.: AVEVA Group plc
Form 8.3 - The Vanguard Group, Inc.: AVEVA Group plc
eqs_en 
0 20.09.22
Form 8.3 - The Vanguard Group, Inc.: AVEVA Group plc
Form 8.3 - The Vanguard Group, Inc.: AVEVA Group plc
Form 8.3 - The Vanguard Group, Inc.: AVEVA Group plc
eqs_en 
0 16.09.22
Form 8.3 - The Vanguard Group, Inc.: AVEVA Group plc
Form 8.3 - The Vanguard Group, Inc.: AVEVA Group plc
Form 8.3 - The Vanguard Group, Inc.: AVEVA Group plc
eqs_en 
0 14.09.22
Form 8.3 - The Vanguard Group, Inc.: AVEVA Group plc
Form 8.3 - The Vanguard Group, Inc.: AVEVA Group plc
Form 8.3 - The Vanguard Group, Inc.: AVEVA Group plc
eqs_en 
0 13.09.22
Form 8.3 - The Vanguard Group, Inc.: AVEVA Group plc
Form 8.3 - The Vanguard Group, Inc.: AVEVA Group plc
Form 8.3 - The Vanguard Group, Inc.: AVEVA Group plc
eqs_en 
0 12.09.22
Form 8.3 - The Vanguard Group, Inc.: AVEVA Group plc
Form 8.3 - The Vanguard Group, Inc.: AVEVA Group plc
Form 8.3 - The Vanguard Group, Inc.: AVEVA Group plc
eqs_en 
0 09.09.22
Form 8.3 - The Vanguard Group, Inc.: AVEVA Group plc
Form 8.3 - The Vanguard Group, Inc.: AVEVA Group plc
Form 8.3 - The Vanguard Group, Inc.: AVEVA Group plc
eqs_en 
0 08.09.22
Form 8 (OPD) - Schneider Electric SE
Form 8 (OPD) - Schneider Electric SE
Form 8 (OPD) - Schneider Electric SE
eqs_en 
0 08.09.22
Form 8 (OPD) - AVEVA Group plc
Form 8 (OPD) - AVEVA Group plc
Form 8 (OPD) - AVEVA Group plc
eqs_en 
0 08.09.22
Block Listing Six Monthly Return
Block Listing Six Monthly Return
Block Listing Six Monthly Return
eqs_en 
0 08.09.22
Form 8.3 - The Vanguard Group, Inc.: AVEVA Group plc
Form 8.3 - The Vanguard Group, Inc.: AVEVA Group plc
Form 8.3 - The Vanguard Group, Inc.: AVEVA Group plc
eqs_en 
0 07.09.22
Form 8.3 - The Vanguard Group, Inc.: AVEVA Group plc
Form 8.3 - The Vanguard Group, Inc.: AVEVA Group plc
Form 8.3 - The Vanguard Group, Inc.: AVEVA Group plc
eqs_en 
0 02.09.22
Form 8.3 - The Vanguard Group, Inc.: AVEVA Group plc
Form 8.3 - The Vanguard Group, Inc.: AVEVA Group plc
Form 8.3 - The Vanguard Group, Inc.: AVEVA Group plc
eqs_en 
0 01.09.22
Form 8.3 - The Vanguard Group, Inc.: AVEVA Group plc
Form 8.3 - The Vanguard Group, Inc.: AVEVA Group plc
Form 8.3 - The Vanguard Group, Inc.: AVEVA Group plc
eqs_en 
0 31.08.22
Form 8.3 - The Vanguard Group, Inc.: AVEVA Group plc
Form 8.3 - The Vanguard Group, Inc.: AVEVA Group plc
Form 8.3 - The Vanguard Group, Inc.: AVEVA Group plc
eqs_en 
0 30.08.22
Form 8.3 - The Vanguard Group, Inc.: AVEVA Group plc
Form 8.3 - The Vanguard Group, Inc.: AVEVA Group plc
Form 8.3 - The Vanguard Group, Inc.: AVEVA Group plc
eqs_en 
0 29.08.22
Form 8.3 - The Vanguard Group, Inc.: AVEVA Group plc
Form 8.3 - The Vanguard Group, Inc.: AVEVA Group plc
Form 8.3 - The Vanguard Group, Inc.: AVEVA Group plc
eqs_en 
0 26.08.22
Form 8.3 - The Vanguard Group, Inc.: AVEVA Group plc
Form 8.3 - The Vanguard Group, Inc.: AVEVA Group plc
Form 8.3 - The Vanguard Group, Inc.: AVEVA Group plc
eqs_en 
0 25.08.22
Director/PDMR Shareholding
Director/PDMR Shareholding
Director/PDMR Shareholding
eqs_en 
0 04.08.22
Correction: Director/PDMR Shareholding
Correction: Director/PDMR Shareholding
Correction: Director/PDMR Shareholding
eqs_en 
0 28.07.22
Director/PDMR Shareholding
Director/PDMR Shareholding
Director/PDMR Shareholding
eqs_en 
0 22.07.22
Form 8.3 - Maitland Institutional Services Limited: Re Tungsten Corp plc
Form 8.3 - Maitland Institutional Services Limited: Re Tungsten Corp plc
Form 8.3 - Maitland Institutional Services Limited: Re Tungsten Corp plc
eqs_en 
0 25.03.22
Form 8.3 - Maitland Institutional Services Limited: Form 8.3 (OPD) - Tungsten Corp Plc
Form 8.3 - Maitland Institutional Services Limited: Form 8.3 (OPD) - Tungsten Corp Plc
Form 8.3 - Maitland Institutional Services Limited: Form 8.3 (OPD) - Tungsten Corp Plc
eqs_en 
0 15.12.21
ADC Therapeutics gibt freiwillige Unterbrechung der Aufnahme in die klinische Phase-II-Studie LOTIS-9 zu ZYNLONTA® (Loncastuximab-Tesirin-Lpyl) und Rituximab bei nicht fitten oder gebrechlichen, zuvor unbehandelten DLBCL-Patienten bekannt
ADC Therapeutics gibt freiwillige Unterbrechung der Aufnahme in die klinische Phase-II-Studie LOTIS-9 zu ZYNLONTA® (Loncastuximab-Tesirin-Lpyl) und Rituximab bei nicht fitten oder gebrechlichen, zuvor unbehandelten DLBCL-Patienten bekannt

LAUSANNE, Schweiz, July 12, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) hat heute eine freiwillige Unterbrechung der Aufnahme neuer Patienten in die klinische Phase-II-Studie LOTIS-9

GlobeNewswire 
0 12.07.23